FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308510109> ?p ?o ?g. }

• W4308510109 endingPage "1361" @default.
• W4308510109 startingPage "1361" @default.
• W4308510109 abstract "Type 2 diabetes mellitus (T2DM) is a potential risk factor for the development of COVID-19 and is associated with higher severity and mortality rates. T2DM patients are commonly treated with metformin monotherapy or metformin plus sitagliptin. In the present case-control, single-center cohort study, a total number of 112 T2DM patients suffering from COVID-19 and aged 44−62 years old were compared with 78 T2DM patients without COVID-19 and aged 42−56 years old. Both the patient group and the control group were allocated into four groups. Group A: T2DM patients with COVID-19 on metformin treatments plus standard therapy (n = 60); group B: T2DM patients with COVID-19 on metformin plus sitagliptin plus standard therapy (n = 52); group C: T2DM patients without COVID-19 on metformin treatments (n = 40); and group D: T2DM patients without COVID-19 on metformin plus sitagliptin (n = 38). The investigation duration was 2−3 weeks. Anthropometric measurements, serological and biochemical investigations, pulmonary radiological findings, and clinical outcomes were evaluated. Only 101 T2DM patients with COVID-19 continued the study, 71 (70.29%) with mild-moderate COVID-19 and 30 (29.7%) with severe COVID-19 were compared with 78 T2DM patients as a control. Inflammatory biomarkers (C reactive protein, ferritin, and procalcitonin), a lung injury biomarker (lactate dehydrogenase), and a coagulopathy biomarker (D-dimer) were elevated in severe COVID-19 patients compared with mild-moderate COVID-19 (p < 0.05) and T2DM patients (p < 0.05). However, metformin plus sitagliptin was more effective than metformin monotherapy in T2DM patients with COVID-19, as evidenced by the mitigation of oxidative stress, CT scan score, and clinical outcomes. The present study confirmed the protective effects of this combination against the development of COVID-19 severity, as most T2DM COVID-19 patients develop mild-moderate forms. Herein, the combination of metformin and sitagliptin may lead to more beneficial effects than metformin monotherapy." @default.
• W4308510109 created "2022-11-12" @default.
• W4308510109 creator A5004116502 @default.
• W4308510109 creator A5006404029 @default.
• W4308510109 creator A5018119690 @default.
• W4308510109 creator A5019363285 @default.
• W4308510109 creator A5027922613 @default.
• W4308510109 creator A5054866724 @default.
• W4308510109 creator A5065518673 @default.
• W4308510109 creator A5066349138 @default.
• W4308510109 creator A5068241143 @default.
• W4308510109 creator A5075437772 @default.
• W4308510109 creator A5080950945 @default.
• W4308510109 creator A5090665178 @default.
• W4308510109 date "2022-11-07" @default.
• W4308510109 modified "2023-10-16" @default.
• W4308510109 title "Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19" @default.
• W4308510109 cites W2027132230 @default.
• W4308510109 cites W2548759197 @default.
• W4308510109 cites W2890320845 @default.
• W4308510109 cites W2909520661 @default.
• W4308510109 cites W2912101697 @default.
• W4308510109 cites W2914024845 @default.
• W4308510109 cites W2982397305 @default.
• W4308510109 cites W2995691142 @default.
• W4308510109 cites W2997621205 @default.
• W4308510109 cites W3008310671 @default.
• W4308510109 cites W3011643491 @default.
• W4308510109 cites W3012421327 @default.
• W4308510109 cites W3015622053 @default.
• W4308510109 cites W3016127017 @default.
• W4308510109 cites W3016311875 @default.
• W4308510109 cites W3017623551 @default.
• W4308510109 cites W3035753382 @default.
• W4308510109 cites W3036199105 @default.
• W4308510109 cites W3040075864 @default.
• W4308510109 cites W3040323020 @default.
• W4308510109 cites W3041333867 @default.
• W4308510109 cites W3042702491 @default.
• W4308510109 cites W3080877256 @default.
• W4308510109 cites W3085361891 @default.
• W4308510109 cites W3092579478 @default.
• W4308510109 cites W3092739271 @default.
• W4308510109 cites W3096317085 @default.
• W4308510109 cites W3104845626 @default.
• W4308510109 cites W3112339069 @default.
• W4308510109 cites W3119899701 @default.
• W4308510109 cites W3130386079 @default.
• W4308510109 cites W3130937313 @default.
• W4308510109 cites W3136768371 @default.
• W4308510109 cites W3154844675 @default.
• W4308510109 cites W3164294216 @default.
• W4308510109 cites W3164435183 @default.
• W4308510109 cites W3186095213 @default.
• W4308510109 cites W3196783092 @default.
• W4308510109 cites W3204168235 @default.
• W4308510109 cites W4205480610 @default.
• W4308510109 cites W4206346269 @default.
• W4308510109 cites W4210866064 @default.
• W4308510109 cites W4213208495 @default.
• W4308510109 cites W4214564310 @default.
• W4308510109 cites W4214858825 @default.
• W4308510109 cites W4225640092 @default.
• W4308510109 cites W4225797073 @default.
• W4308510109 cites W4234265123 @default.
• W4308510109 cites W4282545786 @default.
• W4308510109 cites W4285719527 @default.
• W4308510109 cites W4289653743 @default.
• W4308510109 cites W4299458434 @default.
• W4308510109 doi "https://doi.org/10.3390/ph15111361" @default.
• W4308510109 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36355535" @default.
• W4308510109 hasPublicationYear "2022" @default.
• W4308510109 type Work @default.
• W4308510109 citedByCount "7" @default.
• W4308510109 countsByYear W43085101092023 @default.
• W4308510109 crossrefType "journal-article" @default.
• W4308510109 hasAuthorship W4308510109A5004116502 @default.
• W4308510109 hasAuthorship W4308510109A5006404029 @default.
• W4308510109 hasAuthorship W4308510109A5018119690 @default.
• W4308510109 hasAuthorship W4308510109A5019363285 @default.
• W4308510109 hasAuthorship W4308510109A5027922613 @default.
• W4308510109 hasAuthorship W4308510109A5054866724 @default.
• W4308510109 hasAuthorship W4308510109A5065518673 @default.
• W4308510109 hasAuthorship W4308510109A5066349138 @default.
• W4308510109 hasAuthorship W4308510109A5068241143 @default.
• W4308510109 hasAuthorship W4308510109A5075437772 @default.
• W4308510109 hasAuthorship W4308510109A5080950945 @default.
• W4308510109 hasAuthorship W4308510109A5090665178 @default.
• W4308510109 hasBestOaLocation W43085101091 @default.
• W4308510109 hasConcept C10936531 @default.
• W4308510109 hasConcept C126322002 @default.
• W4308510109 hasConcept C134018914 @default.
• W4308510109 hasConcept C2778384902 @default.
• W4308510109 hasConcept C2779284873 @default.
• W4308510109 hasConcept C2779306644 @default.
• W4308510109 hasConcept C2780323712 @default.
• W4308510109 hasConcept C2910068830 @default.
• W4308510109 hasConcept C555293320 @default.

• next